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Susceptibility to immune rejection represents a major barrier to the success of intraocular transplants of allogeneic and xenogeneic tissue. As in other essential tissue grafts, prevention of graft rejection by creating a state of specific non-responsiveness or tolerance is a major goal of basic research. In the special case of the eye, the phenomenon of immunological �rivilege has been demonstrated experimentally.l, Because of the existence of privilege, it has been anticipated that susceptibility of ocular grafts to rejection would be reduced. In this review, immune privilege in the eye is defined and described in contemporary terms, and strategies for improving intraocular graft survival are considered, based on an understanding of the physiological mechanisms responsible for immune privilege.
Ocular immune privilege can be defined opera tionally as follows: foreign tissues placed in the anterior chamber, the vitreous cavity, the subretinal space and the corneal stroma experience extended (even indefinite) survival compared with similar tissues placed subcutaneously (a conventional site).
Studies in the 1940s and 1950s revealed the internal compartments of the eye to lack a demon strable lymphatic drainage, and it was proposed and accepted at the time that immune privilege could be explained by an 'afferent blockade' in which the systemic immune apparatus never became aware of or recognised antigenic materials placed intraocu larly.1 More recent studies have confirmed that, under normal circumstances, lymphatic drainage from the internal compartments of the eye is minimal. However, immunologists now appreciate that antigenic material also escapes from the eye through the aqueous humour outflow tract. More over, it has recently been determined that prolonged intraocular graft survival is sustained by active immune regulatory mechanisms, rather than by passive ignorance of the graft's existence?, 3 As experimentalists have expanded studies of the fate of tissue grafts placed within the eye, it has become clear that immune privilege is not 'absolute'. This means that not all foreign tissues placed in the Eye (1995) 9, 236-240 © 1995 Royal College of Ophthalmologists eye enjoy indefinite survival; in many instances, a 'honeymoon' period of prolonged acceptance is followed by the emergence of destructive immunity whereupon the graft is destroyed. Since immune privilege in the eye is actively acquired and maintained, hope has arisen that therapeutic strate gies can be devised that would significantly modify graft survival -in positive or negative directions.
On the basis of studies carried out in the mid twentieth century, investigators believed that immune privilege resulted solely from a defect in the process by which antigenic information first reaches the immune system, i.e. a defect in the afferent limb of immune induction was postulated.' Since in many instances systemic immunisation curtailed the survival of intraocular grafts, it was deduced that expression of systemic immunity is 'normal' in the eye, i.e. there was believed to be no defect in the efferent limb of the immune response. However, more critical studies carried out in the last decade have revealed that expression of immunity in the eye is by no means 'normal' or complete. Particularly, it has been reported that expression of cell-mediated immunity, dependent upon T cells of the delayed hypersensitivity type, is grossly impaired in the eye,4 and there is evidence that complement activation is also reduced or absent within the anterior chamber. Thus, the contemporary view is that ocular immune privilege is multifactorial in origin and results from alterations in both induction and expression of immunity to antigens on tissue grafts placed within the eye.
OCULAR IMMUNE PRIVILEGE:
A RATIONALE
As immune privilege in the eye has been found to have a major modifying influence on intraocular graft survival and in other ocular inflammatory disorders, investigators have begun to inquire into the reason for the existence of immune privilege -in the eye, as well as at other sites in the body where privilege is also found (e.g. brain, testis). At present, the dominant view is that immune privilege in the eye represents an evolutionary adaptation that is designed to limit intraocular expression of immuno genic inflammation. Blindness is a powerful selective force, and since immunogenic inflammation within the eye is extremely deleterious to vision, selection has limited expression of this type of immunity within the eye. Ocular immune privilege has been studied in a variety of experimental situations. The phenomenon is now implicated in (1) the extraordinary success of orthotopic corneal allografts, and intraocular retinal cell and tissue transplants,5,6 (2) the unfortunate success of progressively growing intraocular tumours,7 (3) the pathogenesis of stromal keratitis secondary to infection with herpes simplex virus,S (4) the development of acute retinal necrosis following intraocular infection with herpes viruses,9 and (5) protection against, and amelioration of, experimental autoimmune uveoretinis.1O
FEATURES OF THE EYE PERTINENT TO IMMUNE PRIVILEGE
There are biochemical and anatomical features of the eye that appear to be critical to the existence of immune privilege. First, the barrier that exists between the blood and the internal compartments of the eye is extremely important. This barrier, which severely restricts the inflow of blood-borne molecules and cells into the eye, largely prevents specific and non-specific mediators of immunogenic inflammation from gaining access to the eye. Second, the relative lack of lymphatic drainage combined with the bulk flow of aqueous humour through the trabecular meshwork into the canal of Schlemm (and thus into the venous circulation) ensures that antigenic material that escapes the eye does so almost exclusively by the blood route. Consequently, the spleen rather than draining lymph nodes acts as the primary lymphoid organ for the receipt and trans duction of antigenic signals. Third, bone-marrow derived cells with morphological and surface pheno typic characteristics typical of professional antigen presenting cells (APe) are present within the tissues of the eye: iris, ciliary body, retina.'1,l2 However, the functional properties of these cells are distinctly atypical compared with their cellular counterparts at conventional body sites, and the type of immunity evoked br antigens presented by these cells is 'deviant'.' Fourth, ocular fluids contain a unique spectrum of factors (cytokines, neuropetides, growth factors) that suppress immunogenic inflammation and complement activation.'4 To date, aqueous humour has been found to contain physiologically relevant concentrations of transforming growth factor-beta (TGFI3), alpha-melanocyte stimulating hormone, vasoactive intestinal peptide, calcitonin gene-related peptide, and 'anti-complementary activ ity' that has yet to be defined chemically. Moreover, aqueous humour is grossly deficient in cortisol binding globulin;'5 since the concentration of cortisol in aqueous humour approaches that of blood plasma, the 'effective' pharmacological con centration of cortisol in this fluid is quite high, and this probably contributes to the fluid's immunosup pressive features. Taken together, these anatomical and biochemical features contribute to the immune privilege that is extended to foreign tissue grafts placed within the eye. It is likely that experimentalists will identify additional features in the future that make important contributions as well. ACAID has been characterised as distinctive from conventional immune responses in a number of important ways. First, except for highly immuno genic antigens (class I MHC molecules, tumour antigens induced by ultraviolet radiation), ACAID in response to AC-injected antigens is extremely long-lasting. Experimentally. ACAID has been demonstrated to persist in mice for at least 6 months.17 Second, when antigen is injected simulta neously into the AC and into the subcutaneous space, ACAID is routinely induced, rather than conventional immunity. This indicates that ACAID is dominant to conventional immunity, and strongly suggests that both are highly regulated. Third, injection of antigen into the AC of mice pre sensitised conventionally to the same antigen also results in ACAID, indicating that the regulatory mechanisms of ACAID can even suppress pre formed memory and effector T cells that mediate delayed hypersensitivity.Is Fourth, a systemic response identical to ACAID is evoked when antigens are placed in the vitreous cavity or in the subretinal space.19 Thus, immune deviation of the AC type appears to be a property of all three ocular compartments. Fifth, ACAID has now been demon strated following antigen injections into the AC of eyes of mice, rats, and primates (Cynomolgus). 2u
CELLULAR MECHANISM OF ACAID INDUCTION
Two provocative observations have led to an under- This has been demonstrated directly. Conventional APC that are pulsed with antigen in vitro in the presence of TGFI3 (or fluids containing this cytokine) acquire ACAID-inducing potential. When such cells are injected intravenously into naive mice, the latter fail to develop antigen-specific delayed hypersensi tivity when immunised conventionally with antigen in adjuvant. 22 APC that have been exposed to TGFI3 in vitro display unique migration properties when injected intravenously. These cells migrate only to the spleen -not to other lymphoid organs.23 Their ultimate location in the spleen has yet to be determined, but it is likely that they come to rest in an environment containing T lymphocytes. This conclusion has been reached from studies designed to determine whether ACAID-inducing cells are actually functioning as APe. Two types of experiments bear on this issue?4,25 In the first, conventional APC have been incubated with soluble protein antigen (bovine serum albumin, ovalbumin) in the presence of TGFI3; and during this interval, the cells were exposed to the drug chloroquine. This agent prevents acidification of endosomal vesicles and thereby prevents the cleavage of endocytosed protein antigens into immunogenic peptide frag ments. Whereas antigen pulsed cells treated with TGFI3 induced ACAID when injected intravenously, similar cells also exposed to chloroquine failed to induce ACAID. This outcome strongly suggests that in order for cells to promote ACAID they must be able to endocytose soluble protein into vesicles that become acidified. In the second set of experiments, in-vitro-generated ACAID-inducing cells have been injected into allogenic mice selected to determine whether major or minor transplantation antigens act as restricting elements for ACAID induction. The results indicate that in order for ACAID to emerge, the donor and recipient of ACAID-inducing cells must share at least one class I MHC or one class II MHC alloantigen. Donor-recipient pairs that merely share minor histocompatibility antigens do not permit ACAID to develop. Taken together, these results support the view that cells with ACAID inducing capability actually function as APC to self MHC-restricted T cells.
Experiments of this type have been conducted with transgenic mice in which the gene for beta-2 microglobulin (132m) has been deleted. Cells of mice of this type express few, if any, class I MHC molecules. It has now been reported that (1) ACAID cannot be induced by AC injection of soluble antigen into the AC of 132m-deficient mice, and (2) conventional APC obtained from 132m deficient mice fail to acquire ACAID-inducing properties when pulsed with antigen and TGFI3 in vitro. Although a completely satisfying explanation for these results has yet to emerge, the findings emphasise the paramount importance of class I MHC molecules in the genesis of ACAID.
To summarise, immune privilege depends in part upon the induction of ACAID which occurs when antigen is placed within any of several intraocular compartments. ACAID develops because intraocu lar APC, under the influence of local immunomodu latory factors (chiefly TGFI3), capture intraocular antigenic material and migrate with it via the blood to the spleen. At this tissue site, these 'deviant' APC process eye-derived antigens in a unique fashion which enables them to present to, as well as to activate, distinctive regulatory T cells. Importantly, APC bearing eye-derived antigens do not activate delayed hypersensitivity T cells.
ACAID AND OCULAR ALLOGRAFfS
Our laboratory has begun to explore and define the extent to which ACAID participates when immune privilege is extended to ocular allografts in mice and rats. To summarise the most recent work: (1) AC injections of allogeneic lymphoreticular cells (spleen, 239 lymph node, peritoneal exudate cells), or intravenous injections of allogeneic lymphoid cells incubated in vitro with TGFI3 induce ACAID?6 Moreover, both major and minor histocompatibility antigens can induce the phenomenon. (2) AC or vitreous cavity injections of allogenic tumour cells induce ACAID that is permanent (if tumours express only minor histocompatibility antigens) or transient (if tumours express MHC class I alloantigens).27 (3) Long standing, healthy allogeneic corneas grafted orthoto pically into normal mouse eyes are associated with donor-specific ACAID, whereas mice with irrever sibly rejected corneal grafts display no ACAID.5 (4) Pre-emptive induction of ACAID by donor alloanti gens fails to prevent acute rejection of corneal allografts placed in normal mouse eyes (unpub lished observations). Since the mice still display ACAID after the corneal graft has succumbed to rejection, the effector mechanism responsible for rejection must not be T cells that mediate delayed hypersensitivity. (5) Prolonged intraocular accep tance of allogeneic grafts of neonatal neuronal retina, as well as retinal pigment epithelium, is associated with ACAID.19,28 Moreover, if and when these grafts are destroyed immunologically, ACAID disappears and delayed hypersentivity emerges.
We believe that immune privilege and ACAID are important eye-specific processes that protect the eye from the binding effects of immunogenic inflamma tion. Moreover, we believe that these processes play an important role in acceptance of allogeneic tissue grafts designed to restore sight to blinded eyes. However, it must be recalled that the immune system possesses a wide array of effector mechanisms with which solid tissue allografts can be destroyed. Thus, since ACAID appears to interfere only with delayed hypersensitivity and complement fixing antibody expression, grafts placed within the eye of animals with ACAID are nonetheless vulnerable to other destructive effector modalities, such as cytotoxic T cells and non-complement fixing antibodies. Our goal is to identify those forms of intraocular graft rejection that are mediated solely by delayed hypersensitivity, and in these forms to attempt to invoke the protective effects of ACAID.
